Evoked potential abnormality scores are a useful measure of disease burden in relapsing-remitting multiple sclerosis

Fifty patients with relapsing-remitting multiple sclerosis were examined and studied with serial evoked potential and magnetic resonance imaging (MRI) measurements as part of a clinical trial. An evoked potential abnormality score (EPAS) for each testing session was calculated consisting of the tota...

Full description

Saved in:
Bibliographic Details
Published inAnnals of neurology Vol. 44; no. 3; p. 404
Main Authors O'Connor, P, Marchetti, P, Lee, L, Perera, M
Format Journal Article
LanguageEnglish
Published United States 01.09.1998
Subjects
Disability Evaluation
Disease Progression
Evoked Potentials - physiology
Humans
Magnetic Resonance Imaging
Multiple Sclerosis - diagnosis
Multiple Sclerosis - physiopathology
Predictive Value of Tests
Recurrence
Remission, Spontaneous
Research Design
Online AccessGet more information

Cover

More Information
Summary:Fifty patients with relapsing-remitting multiple sclerosis were examined and studied with serial evoked potential and magnetic resonance imaging (MRI) measurements as part of a clinical trial. An evoked potential abnormality score (EPAS) for each testing session was calculated consisting of the total number of abnormal tests. The EPAS correlated well with Expanded Disability Status Scale (EDSS) at years 0, 1, and 2, with Spearman correlation coefficient scores of 0.68, 0.66, and 0.72, respectively. MRI lesion volume correlations ranged from 0.27 to 0.34 for the EDSS. EPAS are a potentially useful surrogate measure of clinical disability in relapsing-remitting multiple sclerosis.
ISSN:0364-5134
DOI:10.1002/ana.410440320